⌘K
Loading ticker…
As of 2026-08-24, Stoke Therapeutics, Inc. Common Stock (STOK) has a 3-month relative strength percentile of 67 within the TickerStance CS+ADRC universe (~5,000 tickers). Its Power rating (absolute 1–99) is 55. The current market Stance is 47.8 (Neutral). Sector: Healthcare, ranked 3 of 11. Average daily range 5.3%, relative volume 0.59×. TickerStance reports observed regime conditions across the full CS+ADRC universe; band assignment reflects current breadth, momentum, and macro inputs computed at the daily close. Percentile ranks run from 1 (weakest) to 99 (strongest) relative to all universe members on the same date.
STOK is in a stage 1 base, week 3. Currently in a 115-day base; basing ADR 5.3% (broad 6.5%). VCP detected: inconclusive. RS line below base-start high. Distance from 50d / 200d: 4.4% / 2.1%.
Relative strength across horizons plus the leadership score.
Accumulation rating, relative volume, U/D ratio, breakout-day proof.
Diluted EPS, last 8 quarters. Loss makers are judged by progress toward breakeven.
STOK appears in 1 ETF as of Jun 2026: PSC at 0.09% weight, $2M notional.
Held by 66 ETFs · $252M across latest filings · largest weight 2.53% (WDNA).
Top 1 by value, from SEC N-PORT-P filings dated Jun 2026.
| ETF | Weight | Value | Δ |
|---|---|---|---|
| PSC | 0.09% | $2M | −0.02 pp |
As filed in N-PORT — quarterly holdings with up to ~60-day publication lag. Not live positioning.
Attention is elevated versus its own recent norm without the relative strength to match — the loud-but-lagging pattern. Worth a skeptical eye; not a short signal.
Measures how unusual this name’s public attention is against its own 90-day history — a surprise reading, not a ranking of how watched it is versus other stocks. Intel, not a signal.
Daily range, ATR, beta, and the math for a 1-ADR stop.
YoY sales growth, last 8 quarters. Sales must back the earnings story.
TTM operating margin. Expansion = real operating leverage.
YoY common shares outstanding. Down = buyback tailwind. Up > 2% = dilution flag.
Reported figures from SEC filings. No analyst estimates or forward guidance.
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | STOK Jan avg: -0.10% median: -0.17% win: 50% σ: 7.36% n: 4 2022-04-12 → 2026-07-31 | STOK Feb avg: 9.39% median: 4.63% win: 50% σ: 39.80% n: 4 2022-04-12 → 2026-07-31 | STOK Mar avg: 10.56% median: -8.44% win: 25% σ: 42.73% n: 4 2022-04-12 → 2026-07-31 | STOK Apr avg: -0.20% median: 0.49% win: 60% σ: 31.28% n: 5 2022-04-12 → 2026-07-31 | STOK May avg: 6.92% median: -2.25% win: 40% σ: 21.16% n: 5 2022-04-12 → 2026-07-31 | STOK Jun avg: 4.25% median: 5.86% win: 60% σ: 10.84% n: 5 2022-04-12 → 2026-07-31 | STOK Jul avg: -2.67% median: 10.81% win: 60% σ: 22.06% n: 5 2022-04-12 → 2026-07-31 | STOK Aug avg: 9.36% median: -0.49% win: 50% σ: 30.49% n: 4 2022-04-12 → 2026-07-31 (current) | STOK Sep avg: -10.31% median: -15.14% win: 25% σ: 20.70% n: 4 2022-04-12 → 2026-07-31 | STOK Oct avg: 10.19% median: 8.11% win: 75% σ: 14.32% n: 4 2022-04-12 → 2026-07-31 | STOK Nov avg: -12.22% median: -1.27% win: 25% σ: 24.76% n: 4 2022-04-12 → 2026-07-31 | STOK Dec avg: 13.74% median: 12.55% win: 75% σ: 21.12% n: 4 2022-04-12 → 2026-07-31 |